Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe Parkinson's disease (PD). Aspen Neuroscience is a private biotechnology company developing personalized regenerative therapies.
The first transplantation procedure in the ASPIRO study was performed by Banner – University Medical Center Tucson neurosurgeon Paul Larson, MD, FAANS, professor of neurosurgery at the University of Arizona College of Medicine – Tucson. The hospital is one of five clinical sites for the Phase 1/2a trial. Dr. Larson is the lead neurosurgeon and Banner – University Medicine Tucson is the lead dosing site for the ASPIRO study.
"First ever successful experimental stem cell therapy for Parkinson's Disease"
BioVie announces treatment of 1st patient in Phase 2 clinical trial of NE3107,ERK inhibitor that selectively inhibits neuroinflammation
